$ONC
BeiGene, Ltd. Stock $onc

$onc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000165130824000051 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q4
Revenue	$929.2M	$751.7M	$4.548B
YoY Change	56.09%	67.85%	68.6%
Cost Of Revenue	$1.009B	$938.2M	$819.4M
YoY Change	951.22%	1047.06%	63.26%
Gross Profit	$791.0M	$626.7M	$3.729B
YoY Change	58.44%	71.23%	69.82%
Gross Profit Margin	85.13%	83.38%	81.98%
Selling, General & Admin	$443.7M	$427.4M	$2.958B
YoY Change	12.33%	30.12%	24.94%
% of Gross Profit	56.09%	68.2%	79.32%
Research & Development	$454.5M	$460.6M	$3.636B
YoY Change	7.5%	12.74%	15.99%
% of Gross Profit	57.45%	73.5%	97.51%
Depreciation & Amortization	$23.75M	$25.29M
YoY Change	11.48%	26.4%
% of Gross Profit	3.0%	4.04%
Operating Expenses	$898.2M	$888.1M	$6.589B
YoY Change	9.83%	20.48%	19.39%
Operating Profit	-$107.2M	-$261.3M	-$2.860B
YoY Change	-66.38%	-29.6%	-13.93%
Interest Expense	$5.220M	$71.41M	$236.1M
YoY Change	-101.28%	-30.4%	-4.25%
% of Operating Profit
Other Income/Expense, Net	-$11.98M	$1.762M	-$902.0K
YoY Change	-81.22%	-90.37%	-26.0%
Pretax Income	-$105.9M	-$243.4M	-$2.625B
YoY Change	-71.18%	-27.75%	-14.71%
Income Tax	$14.49M	$7.724M	$212.9M
% Of Pretax Income
Net Earnings	-$120.4M	-$251.2M	-$2.838B
YoY Change	-68.41%	-27.92%	-11.55%
Net Earnings / Revenue	-12.96%	-33.41%	-62.39%
Basic Earnings Per Share	-$0.09	-$0.19
Diluted Earnings Per Share	-$0.09	-$0.19	-$2.11
COMMON SHARES
Basic Shares Outstanding	1.360B shares	1.360B shares	1.359B shares
Diluted Shares Outstanding	1.361B shares	1.356B shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.72B	$20.13B	$22.55B
YoY Change	-24.42%	-17.22%	-15.82%
Cash & Equivalents	$2.593B	$2.793B	$3.172B
Short-Term Investments	$6.457B	$5.720B	$7.515B
Other Short-Term Assets	$1.322B	$1.205B	$1.083B
YoY Change	-49.46%	-68.89%	-82.36%
Inventory	$443.3M	$447.3M	$416.1M
Prepaid Expenses
Receivables	$529.4M	$435.3M	$358.0M
Other Receivables	$599.0M	$346.5M	$685.6M
Total Short-Term Assets	$3.839B	$3.908B	$4.203B
YoY Change	-12.78%	-16.93%	-19.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.516B	$1.418B	$1.324B
YoY Change	46.96%	53.23%	56.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$37.78M	$41.12M	$25.98M
YoY Change	25.85%	27.04%	-6.24%
Other Assets	$199.3M	$199.0M	$125.4M
YoY Change	35.09%	14.8%	-26.44%
Total Long-Term Assets	$1.873B	$1.760B	$1.602B
YoY Change	41.12%	40.52%	36.65%
TOTAL ASSETS
Total Short-Term Assets	$3.839B	$3.908B	$4.203B
Total Long-Term Assets	$1.873B	$1.760B	$1.602B
Total Assets	$5.712B	$5.668B	$5.805B
YoY Change	-0.29%	-4.85%	-9.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$333.0M	$356.6M	$315.1M
YoY Change	24.74%	47.74%	6.9%
Accrued Expenses	$646.5M	$569.4M	$693.7M
YoY Change	42.11%	36.25%	48.44%
Deferred Revenue			$0.00
YoY Change			-100.0%
Short-Term Debt	$5.871B	$5.689B	$4.684B
YoY Change	101.87%	210.23%	112.63%
Long-Term Debt Due	6.189B cnies	5.971B cnies	4.886B cnies
YoY Change	102.72%	208.51%	115.34%
Total Short-Term Liabilities	$1.939B	$1.882B	$1.810B
YoY Change	37.98%	49.99%	23.26%
LONG-TERM LIABILITIES
Long-Term Debt	1.346B cnies	1.437B cnies	1.403B cnies
YoY Change	-10.48%	1.43%	-2.76%
Other Long-Term Liabilities	$51.53M	$48.90M	$50.51M
YoY Change	19.52%	7.19%	9.58%
Total Long-Term Liabilities	$407.2M	$425.6M	$457.8M
YoY Change	-22.46%	-21.89%	-13.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.939B	$1.882B	$1.810B
Total Long-Term Liabilities	$407.2M	$425.6M	$457.8M
Total Liabilities	$2.346B	$2.307B	$2.268B
YoY Change	21.54%	28.22%	13.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$8.334B	-$8.213B	-$7.962B
YoY Change	6.71%	10.56%	12.45%
Common Stock	$137.0K	$136.0K	$135.0K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.366B	$3.360B	$3.537B
YoY Change
Total Liabilities & Shareholders Equity	$5.712B	$5.668B	$5.805B
YoY Change	-0.29%	-4.85%	-9.0%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$120.4M	-$251.2M	-$2.838B
YoY Change	-68.41%	-27.92%	-11.55%
Depreciation, Depletion And Amortization	$23.75M	$25.29M
YoY Change	11.48%	26.4%
Cash From Operating Activities	-$706.7M	-$308.6M	-$2.392B
YoY Change	-53.68%	-45.27%	78.37%
INVESTING ACTIVITIES
Capital Expenditures	$856.3M	$156.6M	$1.009B
YoY Change	-14.89%	24.68%	17.14%
Acquisitions
YoY Change
Other Investing Activities	-$576.4M	$19.43M	-$1.697B
YoY Change	-127.28%	110.1%	-55.51%
Cash From Investing Activities	-$1.433B	-$209.8M	-$2.706B
YoY Change	-229.46%	-187.04%	-42.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$3.579M
YoY Change		145.64%
Cash From Financing Activities	68.05M	$162.3M	2.308B
YoY Change	-93.8%	-916.86%	-358.94%
NET CHANGE
Cash From Operating Activities	-706.7M	-$308.6M	-2.392B
Cash From Investing Activities	-1.433B	-$209.8M	-2.706B
Cash From Financing Activities	68.05M	$162.3M	2.308B
Net Change In Cash	-2.071B	-$378.5M	-2.790B
YoY Change	-405.28%	14.27%	-59.61%
FREE CASH FLOW
Cash From Operating Activities	-$706.7M	-$308.6M	-$2.392B
Capital Expenditures	$856.3M	$156.6M	$1.009B
Free Cash Flow	-$1.563B	-$465.2M	-$3.401B
YoY Change	-38.27%	-32.52%	54.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	751652000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	447801000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	626717000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	366012000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	460638000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	408584000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	427427000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	328499000	usd
CY2024Q1	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	0	usd
CY2023Q1	bgne	Amortization Of Intangible Assets Included In Operating Expenses AmortizationOfIntangibleAssetsIncludedInOperatingExpenses	187000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	888065000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	737270000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-261348000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-371258000	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16160000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	16016000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1762000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18303000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-243426000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-336939000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7724000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11492000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-251150000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1355547626	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1355547626	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1354164760	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1354164760	shares
CY2024Q1	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-2.41
CY2024Q1	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-2.41
CY2023Q1	bgne	Earnings Per American Depository Share Diluted EarningsPerAmericanDepositoryShareDiluted	-3.34
CY2023Q1	bgne	Earnings Per American Depository Share Basic EarningsPerAmericanDepositoryShareBasic	-3.34
CY2024Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	104272894	shares
CY2024Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	104272894	shares
CY2023Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Diluted WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted	104166520	shares
CY2023Q1	bgne	Weighted Average Number Of American Depository Shares Outstanding Basic WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic	104166520	shares
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-251150000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-348431000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-32163000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	13347000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-35000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5056000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-283348000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-330028000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2793370000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3171800000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2600000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	435294000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	358027000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	447345000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	416122000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231741000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	254865000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3907750000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4203414000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1417992000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1324154000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	87747000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	95207000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55171000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57138000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	199021000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125362000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1759931000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1601861000	usd
CY2024Q1	us-gaap	Assets Assets	5667681000	usd
CY2023Q4	us-gaap	Assets Assets	5805275000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	356575000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	315111000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	569438000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	693731000	usd
CY2024Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	27324000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	22951000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19401000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21950000	usd
CY2024Q1	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	81986000	usd
CY2023Q4	bgne	Research And Development Cost Share Liability Current Portion ResearchAndDevelopmentCostShareLiabilityCurrentPortion	68004000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	826965000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	688366000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1881689000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1810113000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	199027000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197618000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17722000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22251000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16437000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16494000	usd
CY2024Q1	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	143544000	usd
CY2023Q4	bgne	Research And Development Cost Share Liability Noncurrent Portion ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion	170662000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48901000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50810000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	425631000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	457835000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2307320000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2267948000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	9500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1359524369	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1359524369	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1359513224	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1359513224	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	136000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	135000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11705069000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11598688000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-131644000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-99446000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8213200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7962050000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3360361000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3537327000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5667681000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5805275000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-251150000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-348431000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25293000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20011000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	88667000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	75322000	usd
CY2024Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	3735000	usd
CY2023Q1	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	usd
CY2024Q1	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-13136000	usd
CY2023Q1	bgne	Amortization Of Research And Development Financing Liability AmortizationOfResearchAndDevelopmentFinancingLiability	-17398000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	848000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	780000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	80025000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	136487000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	37264000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13027000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4401000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	50408000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	46300000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-22589000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-79309000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-38681000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-33066000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-660000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	197000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-308572000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-563777000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156578000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125585000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4674000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	2655000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	376962000	usd
CY2024Q1	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	31800000	usd
CY2023Q1	bgne	Payments To Purchase In Process Research And Development PaymentsToPurchaseInProcessResearchAndDevelopment	0	usd
CY2024Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	19434000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	10314000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-209831000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	241063000	usd
CY2024Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	9053000	usd
CY2023Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3579000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1457000	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	142028000	usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	50000000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14791000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	31589000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	162293000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-19868000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22438000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11311000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-378548000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-331271000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3185984000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3875037000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2807436000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3543766000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2793370000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3538644000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11445000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	159000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2621000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4963000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2490000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7616000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	11440000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	5017000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100473000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	64013000	usd
CY2024Q1	bgne	Noncash Investing And Financing Items Increase In Equity Investment NoncashInvestingAndFinancingItemsIncreaseInEquityInvestment	40798000	usd
CY2023Q1	bgne	Noncash Investing And Financing Items Increase In Equity Investment NoncashInvestingAndFinancingItemsIncreaseInEquityInvestment	0	usd
CY2024Q1	bgne	Adjustments To Additional Paid In Capital Deconsolidation Of Subsidiary AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary	2052000	usd
CY2024Q1	bgne	Number Of Approved Medicines NumberOfApprovedMedicines	3	medicine
CY2024Q1	bgne	Number Of Internal Clinical Teams NumberOfInternalClinicalTeams	3000	person
CY2024Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	10000	employee
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.</span></div>
CY2024Q1	bgne	Reimbursement Expense ReimbursementExpense	10289000	usd
CY2023Q1	bgne	Reimbursement Expense ReimbursementExpense	11583000	usd
CY2024Q1	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	35027000	usd
CY2023Q1	bgne	Upfront And Milestone Payments UpfrontAndMilestonePayments	0	usd
CY2024Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	11445000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11473000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2621000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2711000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	14066000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	14184000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	2600000	usd
CY2024Q1	us-gaap	Equity Method Investments EquityMethodInvestments	41119000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	25981000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	139012000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	85429000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1412000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1107000	usd
CY2024Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	797000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	1081000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-856000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-144000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	157735000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	148772000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	49365000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	39098000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	240245000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	228252000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	447345000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	416122000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	900137000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	832751000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	265002000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	249212000	usd
CY2024Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	782857000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	740615000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1417992000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1324154000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	24110000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	19025000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	72400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17229000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55171000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	73261000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16123000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	57138000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1183000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	986000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3600000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4777000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4777000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4777000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4777000	usd
CY2024Q1	bgne	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	32463000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55171000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7724000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11492000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14924000	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	660000	usd
CY2024Q1	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	66772000	usd
CY2023Q4	bgne	Prepaid Research And Development Costs PrepaidResearchAndDevelopmentCosts	60476000	usd
CY2024Q1	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	42225000	usd
CY2023Q4	bgne	Prepaid Manufacturing Costs PrepaidManufacturingCosts	42066000	usd
CY2024Q1	us-gaap	Prepaid Taxes PrepaidTaxes	32686000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	37320000	usd
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	31818000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	37859000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11445000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11473000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	7899000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8872000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	38896000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	56799000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	231741000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	254865000	usd
CY2024Q1	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	30834000	usd
CY2023Q4	bgne	Prepayment Of Long Term Asset PrepaymentOfLongTermAsset	4144000	usd
CY2024Q1	bgne	Prepaid Supply Cost PrepaidSupplyCost	13044000	usd
CY2023Q4	bgne	Prepaid Supply Cost PrepaidSupplyCost	18122000	usd
CY2024Q1	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	2756000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Noncurrent ValueAddedTaxReceivableNoncurrent	2546000	usd
CY2024Q1	bgne	Rental Deposits And Other RentalDepositsAndOther	6151000	usd
CY2023Q4	bgne	Rental Deposits And Other RentalDepositsAndOther	8195000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2621000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2711000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	143615000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	89644000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	199021000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125362000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	114657000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	217803000	usd
CY2024Q1	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	99009000	usd
CY2023Q4	bgne	Accrued Liabilities External Research And Development AccruedLiabilitiesExternalResearchAndDevelopment	162969000	usd
CY2024Q1	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	74747000	usd
CY2023Q4	bgne	Accrued Expenses Commercial Activities AccruedExpensesCommercialActivities	87572000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	47229000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	30083000	usd
CY2024Q1	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	186277000	usd
CY2023Q4	bgne	Accrued Sales Rebates And Returns Current AccruedSalesRebatesAndReturnsCurrent	139936000	usd
CY2024Q1	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	47519000	usd
CY2023Q4	bgne	Accrued Professional Fees And Other Current AccruedProfessionalFeesAndOtherCurrent	55368000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	569438000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	693731000	usd
CY2024Q1	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	32939000	usd
CY2023Q4	bgne	Government Grants Or Incentives Received And Deferred Noncurrent GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent	34204000	usd
CY2024Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	14428000	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	14995000	usd
CY2024Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	1108000	usd
CY2023Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	1127000	usd
CY2024Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	426000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	484000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	48901000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50810000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	826965000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5970864000	cny
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	688366000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4885838000	cny
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	199027000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1437019000	cny
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	197618000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1402643000	cny
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	12404000	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	4574000	usd
CY2024Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	9209000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	344000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-251150000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-348431000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1355547626	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1355547626	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1354164760	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1354164760	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	88714000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75388000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-32198000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-32198000	usd
CY2024Q1	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2024Q1	bgne	Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital	0.50
CY2024Q1	bgne	Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage	0.10
CY2024Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	93511000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	751652000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	447801000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001651308-24-000051-index-headers.html	Edgar Link	pending
0001651308-24-000051-index.html	Edgar Link	pending
0001651308-24-000051.txt	Edgar Link	pending
0001651308-24-000051-xbrl.zip	Edgar Link	pending
bgne-20240331.htm	Edgar Link	pending
bgne-20240331.xsd	Edgar Link	pending
bgne-20240331_g1.jpg	Edgar Link	pending
exhibit102-2024consultinga.htm	Edgar Link	pending
exhibit311-2024q1.htm	Edgar Link	pending
exhibit312-2024q1.htm	Edgar Link	pending
exhibit321-2024q1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
bgne-20240331_def.xml	Edgar Link	unprocessable
bgne-20240331_lab.xml	Edgar Link	unprocessable
bgne-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bgne-20240331_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bgne-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONC
BeiGene, Ltd. Stock $onc

2024 Q2 Form 10-Q Financial Statement

#000165130824000051 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC BeiGene, Ltd. Stock $onc

2024 Q2 Form 10-Q Financial Statement

#000165130824000051 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONC
BeiGene, Ltd. Stock $onc